INVESTOR ALERT: Investigation of Albany Molecular Research Inc. Announced by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Albany Molecular Research Inc. (“Albany Molecular” or the “Company”) (NASDAQ:AMRI) concerning possible violations of federal securities laws. The investigation is focused on the Company’s operations and financial performance.

Please contact Lesley Portnoy at (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

Albany Molecular is a contract research and manufacturing company that provides integrated drug discovery, development and manufacturing services primarily in the United States, Europe and Asia. The investigation is related to the Company’s November 5, 2014, announcement of weak financial and operating results for third quarter 2014, including an $8.6 million loss in the quarter. The Company attributed the weak third quarter to a “confluence of a business interruption event at our OsoBio facility, together with lower Discovery and API revenue.” In addition, the Company disclosed a “weather-related power interruption at our OsoBio facility in Albuquerque took the facility offline for a period of time, contributing to the loss of finished product and the need to remediate one of the suites at the facility.” The Company now expects full-year earnings in the range of $0.67 to $0.73 per share on revenue in the range of $278 million to $286 million, well below the consensus estimate.

If you purchased Albany Molecular securities, if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at (310) 201-9150, Toll Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.